Skip to content
value.today
World rank
#22,792
Revenue
$8 M
For year ending December-2025
Net income
$-15 M
-195.7% margin
SEC filing
Employees
46
As of March 2, 2026
SEC filing

Biolargo Inc. in brief

Biolargo Inc. is a listed company in the Chemicals industry, based in Westminster, California, USA. Its market value was $32 M on 1 August 2026, which makes it the 22,792nd largest listed company in the world and the 4,023rd largest in the USA on this site. In the year to December 2025 it had sales of $8 M and a net loss of $15 M. It employs about 46 people. Its largest business segments by sales in 2025 were Odor-No-More (76%), BioLargo Engineering, Science & Technologies, LLC (33%) and BioLargo Canada (1%).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Biolargo Inc.

BioLargo, Inc. is a corporation organized under the laws of the state of Delaware. Our common stock is quoted on the OTC Markets highest level marketplace, the OTCQX, under the trading symbol “BLGO”.

Our corporate offices are located at 14921 Chestnut St., Westminster, California 92683. We have a research facility and offices at the University of Alberta in Canada, and our engineering team is located at 105 Fordham Road in Oak Ridge, Tennessee. Our medical products company is located at 10770 N. 46th Street, Unit C-300, in Tampa, Florida. Our telephone number is (888) 400-2863. We operate through multiple wholly- and partially-owned subsidiaries.

From the company's annual report filed with the US SEC: read the report

Biolargo Inc. timeline

5 events, 1996–2024
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2001
  4. ✎
    Renamed Nuway Energy Inc
    Formerly Latin American Casinos Inc.
  5. 2003
  6. ✎
    Renamed Nuway Medical Inc
    Formerly Nuway Energy Inc.
  7. 2007
  8. ✎
    Renamed Biolargo, Inc.
    Formerly Nuway Medical Inc.
  9. 2024
  10. 💰
    Record revenue of $18 million
    FY2024, the highest of the 8 years on record.

Events of Biolargo Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$14 M$29 M$43 M$57 M2023202420252026

World rank over time

▲ up 6,482 places since 2022
2022-01-07: #27123#27,12320222022-12-25: #25417#25,41720222023-07-30: #24928#24,92820232026-08-01: #20641#20,6412026

Rank in USA: #4,885 (Jan 2022) · #4,814 (Dec 2022) · #4,697 (Jul 2023) · #3,859 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
7.9×
Price / book
7.9×
Free cash flow yield
-13.5%
Net margin (TTM)
-377.6%
Operating margin
-191.5%
Return on equity
-380.4%
Liabilities / assets
81.6%
Net debt
$-2M
Revenue growth
-56.4%
R&D / revenue
33.4%
Revenue per employee
$169 K
Profit per employee
$-330 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1M, net income $-11M$1MFY18Fiscal year ending Dec 2019: revenue $2M, net income $-11M$2MFY19Fiscal year ending Dec 2020: revenue $2M, net income $-10M$2MFY20Fiscal year ending Dec 2021: revenue $3M, net income $-7M$3MFY21Fiscal year ending Dec 2022: revenue $6M, net income $-5M$6MFY22Fiscal year ending Dec 2023: revenue $12M, net income $-5M$12MFY23Fiscal year ending Dec 2024: revenue $18M, net income $-4M$18MFY24Fiscal year ending Dec 2025: revenue $8M, net income $-15M$8MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$8M-56.4%$-15M$-15M-195.7%
Dec 2024$18M+45.4%$-4M$-4M-24.5%
Dec 2023$12M+108.0%$-5M$-5M-38.0%
Dec 2022$6M+132.4%$-5M$-5M-87.2%
Dec 2021$3M+4.1%$-7M$-7M-272.3%
Dec 2020$2M+30.6%$-8M$-10M-399.2%
Dec 2019$2M+36.8%$-7M$-11M-615.1%
Dec 2018$1M—$-6M$-11M-786.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-8M————
Dec 2024$-3M————
Dec 2023$-2M————
Dec 2022$-3M————
Dec 2021$-4M——$-0.03—
Dec 2020$-4M——$-0.05—
Dec 2019$-4M——$-0.08—
Dec 2018$-4M——$-0.09—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$4M
Net income, trailing 12 months
$-15M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $4M, net income $-2M$4MDec ’24Three months to Mar 2025: revenue $3M, net income $-2M$3MMar ’25Three months to Jun 2025: revenue $3M, net income $-2M$3MJun ’25Three months to Sep 2025: revenue $1M, net income $-7M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-4M$1MDec ’25Three months to Mar 2026: revenue $1M, net income $-3M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $-4M$1MJun ’26Three months to Sep 2026: revenue $1M, net income $-4M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (-0.9% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Biolargo Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$8 M
Operating income
$-15 M
Net income
$-15 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$8 M
Total liabilities
$7 M
Total equity
$4 M

As of December-2025

Top 1 institutional investors in Biolargo Inc.#

As of Sep 30, 2026
1 institutions held 117,838 shares (about 0.0% of the shares outstanding) on Sep 30, 2026. Filings read through Nov 12, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 1 largest institutional investors in Biolargo Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1First American Trust, FSB117,8380 (0.00%)0.04%$0 MNov 12, 2026

Insider trading at Biolargo Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
9
since
Biolargo Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Dennis P. CalvertPresident, DirectorGrant or award+931,886$0.080$75 K11.99 MForm 4
filed Kenneth Reay CodeChief Science Officer, DirectorGrant or award+566,261$0.080$45 K26.97 MForm 4
filed Dennis P. CalvertPresident, DirectorGift+2.00 M——13.99 MForm 4
filed Kenneth Reay CodeChief Science Officer, DirectorGift-2.00 M——24.97 MForm 4
filed Kenneth Reay CodeChief Science Officer, DirectorGrant or award+532,567$0.110$59 K26.41 MForm 4
filed Dennis P. CalvertPresident, DirectorGrant or award+219,914$0.110$24 K11.06 MForm 4
filed Dennis P. CalvertPresident, DirectorGrant or award+699,569$0.110$77 K10.84 MForm 4
filed Kenneth Reay CodeChief Science Officer, DirectorGrant or award+69,444$0.160$11 K25.88 MForm 4

Biolargo Inc. scorecard#

Passes 6 of the 16 checks that could be worked out: strongest in growth (3 of 5), weakest in profitability (0 of 5). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
  • Growth3 of 5
  • Profitability0 of 5
  • Financial health3 of 6
  • Shareholder returnsnot known

Worked out from the statements as filed (sec), the medians of Chemicals, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Biolargo Inc.'s statements, beside the median of Chemicals.

Biolargo Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-191.5%4.7%
Net margin-195.8%2.2%
Return on equity-235.7%2.1%
Revenue growth, 3 years a year9.7%-2.4%
Revenue growth-56.4%0.4%
Debt to equity0.51×0.64×

1of 8on the Piotroski tests of financial strength

  • Revenue fell 56.4% against the year before.
  • Net loss of $15 million, the 16th loss-making year in a row.
  • Operating income covers the interest bill only -27.5 times.
  • More cash than debt: net cash of $2 million.

Biolargo Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Biolargo Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue7.818125.92.52.41.91.40.5r0.3
Cost of revenue4.49.96.13.01.41.20.90.70.3r0.1
Gross profit3.47.96.22.91.11.20.90.60.2r0.2
Research and development2.62.92.31.31.41.31.51.71.6r1.4
Selling, general and administrative129.38.16.76.27.56.15.3r4.4r3.7
Operating expenses1812118.27.9r8.87.67.06.1—
Operating income−15−4.3−4.6−5.4−6.8r−7.6−6.7−6.4−5.9r−4.9
Interest and finance income0.20.0r————————
Interest expense and finance costs0.50.1r0.10.10.21.94.03.53.9r3.1
Net interest income−0.3−0.0−0.1−0.1——————
Share of profit of associates−0.0−0.0−0.0−0.0−0.0−0.0————
Other non-operating income (expense)−0.3−0.0−0.10.3−0.1r−2.1−4.7−4.3−3.7r−3.1
Income before tax−15−4.3————————
Income tax—00———————
Net income including minority interests−15−4.3−4.6−5.1−6.9−9.7−11−11−9.5r−8.1
Minority interests' share of net income−3.4−1.9−1.1−0.70.2————−0.2
Earnings per share, basic-0.04-0.01-0.01r-0.02-0.03-0.05-0.08-0.09-0.10-0.09
Earnings per share, diluted————-0.03-0.05-0.08-0.09-0.10-0.09
Shares, weighted average (basic)3072982862682471961521229988
Balance sheet
Cash and cash equivalents3.93.53.51.91.00.70.70.71.0r1.9r
Receivables0.63.22.61.10.50.50.40.30.1r0.1
Inventory0.30.30.20.1r0.20.30.00.00.1r0.0
Other current assets0.30.10.10.1r0.10.00.00.00.00.0
Current assets5.17.16.43.21.81.51.11.01.2r2.0
Property, plant and equipment1.61.70.70.30.10.10.10.10.1r0.1
Right-of-use (leased) assets1.01.01.10.90.50.30.4———
Other intangible assets———4.93.0r2.21.91.9——
Investments in associates00.00.00.00.00.1————
Non-current assets————1.23.4————
Total assets8.3118.24.93.04.93.63.21.5r2.1
Accounts payable1.00.81.20.70.40.30.2r0.30.1r0.0
Debt due within a year—0.1r0.10.10.31.2r4.1r2.25.2r0.6r
Current liabilities5.12.62.71.61.43.54.42.54.2r1.2
Long-term debt——0.30.20.20.50.71.31.5r5.3
Lease liabilities (non-current)0.90.91.00.80.30.20.3r———
Non-current liabilities1.71.81.31.30.71.6—1.8——
Total liabilities6.84.54.02.82.15.25.84.34.9r2.9
Retained earnings−161−150−147−144−139−132−123−112−101r−92
Shareholders' equity4.08.96.84.94.73.9−2.2−1.5−4.1r−1.3
Minority interests−2.5−2.8−2.6−2.9−3.7−4.1−0.00.40.7r0.6
Total equity1.56.14.22.00.9−0.2−2.2−1.1−3.4r−0.8r
Total liabilities and equity8.3118.24.93.04.93.63.21.5r2.1
Shares outstanding——293278——166——93
Cash-flow statement
Depreciation and amortization——0.10.00.00.10.10.10.0r0.0
Share-based compensation3.02.12.12.11.92.51.51.31.1r0.8
Cash from operating activities−8.3−3.2−2.4−2.8−3.9−4.2−4.4−3.9−4.3r−3.7
Capital expenditure————————−0.0—
Intangible assets bought———0−0.00————
Cash from investing activities0.4−1.3−0.5−0.3−0.0−0.1−0.0−0.1−0.0r−0.1
Shares issued2.00.62.23.64.92.80.10.80.5r—
Cash from financing activities8.24.44.74.04.24.34.53.63.4r4.0
Exchange-rate effect on cash——————−0.0−0.00.0r−0.0
Change in cash0.30.01.70.90.20.1—−0.3−0.9r0.1
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Jun 30, 2026

What Biolargo Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$6 M74%
  • Service(total)$2 M26%

Business segments

  • Odor-No-More$6 M76%
  • BioLargo Engineering, Science & Technologies, LLC$3 M33%
  • BioLargo Canada$0 M1.1%

As of Dec 31, 2025

Executive pay at Biolargo Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$318 K
Other top executives, average
$252 K
the CEO earned 1.3× this
$100 invested is now
$90
Biolargo Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$318 K$318 K$252 K$90
2024Chief executive$318 K$318 K$266 K$90
2023Chief executive$317 K$299 K$215 K$79

As of Dec 31, 2025

Events at Biolargo Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

Impairment 1 · Material agreement 1 · Agreement ended 1 · Unregistered share sale 1 · Shareholder vote 2

Biolargo Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementUnregistered share sale8-K
ImpairmentAgreement ended8-K
Shareholder vote8-K
Shareholder vote8-K

As of Mar 25, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Biolargo Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2012$1 MNo. 2Under $2 million32equity, optionsSEC
Aug 2010$1 MNo. 1Under $2 million41equitySEC

Lobbying by Biolargo Inc.#

$20 K spent on lobbying the US Congress and federal agencies in 2025.

Lobbying, 2025
$20 K
#1,438 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
—

Lobbying firms hired in 2025

J.A. Green and Company (formerly LLC) $20 K

Biolargo Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2025$20 K—2
2024$80 K—4
2023$30 K—2

How Biolargo Inc. compares in Chemicals

  • Market cap$32 M · higher than 16% of 1,115
  • Revenue$8 M · higher than 3% of 421
  • Net margin-377.6% · higher than 0% of 409
  • Revenue growth-56.4% · higher than 4% of 111
  • Price / sales7.9× · lower than 11% of 382
  • Price / book7.9× · lower than 11% of 345
  • FCF yield-13.5% · higher than 13% of 80

Peer comparison · Chemicals

CompanyMarket capP/ENet marginRev. growth
Biolargo Inc.🇺🇸$32 M—-377.6%-56.4%
Linde plc🇬🇧$231.0 B33.0×19.3%+3.0%
Air Liquide🇫🇷$124.8 B29.9×13.1%+3.8%
The Sherwin-Williams Company🇺🇸$81.4 B30.4×10.7%+2.1%
Ecolab Inc.🇺🇸$79.7 B38.3×12.0%+2.2%
Shin-Etsu Chemical Co., Ltd.🇯🇵$74.3 B23.1×18.4%—
Air Products and Chemicals, Inc.🇺🇸$66.5 B125.0×4.1%+7.9%
BASF SE🇩🇪$52.7 B27.4×2.7%-18.8%
Nan Ya Plastics Corporation🇹🇼$49.7 B336.2×1.7%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 2, 2026
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Biolargo Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Biolargo Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Biolargo Inc.? Suggest a correction